p73 encodes multiple functionally distinct isoforms. Proapoptotic TAp73 isoforms contain a transactivation (TA) domain, and like p53, have tumor suppressor properties and are activated by chemotherapies to induce cell death. In contrast, antiapoptotic DNp73 isoforms lack the TA domain and are dominant-negative inhibitors of p53 and TAp73. DNp73 proteins are overexpressed in a variety of tumors including neuroblastoma. Thus, identification of drugs that upregulate TAp73 and/or downregulate DNp73 represents a potential therapeutic strategy. Here, we report that cyclooxygenase (COX) inhibitors induce apoptosis independent of p53, and differentially modulate endogenous p73 isoforms in neuroblastoma and other tumors. COX inhibitor-mediated apoptosis is associated with the induction of TAp73b and its target genes. COX inhibitors also downregulate the alternative-spliced DNp73 AS isoforms, Dexon2 and Dexon2/3. Furthermore, forced expression of DNp73
Introduction
The p53 family consists of three closely related proteins (p53, p63 and p73) that share significant homology. The role of p53 in mediating chemosensitivity is well established. Recently, evidence has emerged that the p53 family proteins form an intricate network involved in tumorigenesis, as well as response to chemotherapy (Irwin, 2004) . p53 is defective in the majority of cancers due to mutation or inactivation. To overcome chemoresistance, it is, therefore, important to devise therapeutic strategies that restore the function of wild-type (wt) p53 or alternatively, in the presence of mutant-p53, engage p73 to activate apoptotic pathways. Unlike p53, p73 is rarely mutated in cancers. p73 encodes multiple functionally distinct isoforms due to alternative promoter (AP) utilization and mRNA splicing. The TAp73 proteins have a transactivation (TA) domain and can transcriptionally activate p53-responsive genes to induce apoptosis. Induction of TAp73 has been linked to chemosensitivity (Irwin et al., 2003) . In contrast, DNp73 isoforms lack the TA domain and act as dominantnegative inhibitors of the full-length (FL) p53 and p73 proteins (Irwin, 2004) . DNp73 isoforms (also called DTAp73) include the DNp73 AS isoforms generated by alternative splicing (AS) at the NH 2 -terminus and the DNp73 AP isoform transcribed from an AP located in intron 3 (Figure 1 ). The overexpression of DNp73 isoforms occurs in a variety of cancers and has also been identified as a poor prognostic marker in patients with ovarian (Concin et al., 2005) , hepatocellular (Muller et al., 2005) , colon and breast cancers (Dominguez et al., 2006) , and in children with neuroblastoma (Casciano et al., 2002) . p73 splice variants are also generated at the COOH-terminus (a-y), and these proteins possess some differences in their intrinsic ability to induce target genes and apoptosis. For example, TAp73b transactivates proapoptotic target genes to a greater extent than TAp73a (Gonzalez et al., 2005) . However, little is known about the specific expression pattern and regulation of different COOH-variants in human tumors.
Hence, therapeutic modulation of p73 isoforms, by way of promoting TAp73 activity and/or downregulating DNp73, may represent an effective strategy to enhance chemosensitivity. We and others have reported that cyclooxygenase (COX) inhibitors induce cell death and enhance chemosensitivity in neuroblastoma (Johnsen et al., 2004; Lau et al., 2007; Ponthan et al., 2007) . COX inhibitors are non-steroidal anti-inflammatory drugs commonly used as analgesics and anti-inflammatory agents, but have also been shown to have anticancer properties (Thun et al., 2002) . The COX enzyme catalyses the conversion of arachidonic acid to prostaglandins. Nonselective COX inhibitors inhibit both the COX-1 and COX-2 isoforms, whereas selective COX-2 inhibitors inhibit the COX-2 isoform. In addition, COX inhibitors have also been shown to target COX-2 independent signaling pathways (reviewed in Kashfi and Rigas (2005) and Grosch et al. (2006) ). We have shown that COX inhibitors modulate the p53/HDM2 pathway, resulting in increased p53 stability and nuclear accumulation (Lau et al., 2007) . We observed that neuroblastoma cells harboring mutant-p53 were also sensitive to COX inhibitors, prompting us to ask whether p73 was involved in the potentiation of chemosensitivity by COX inhibitors. In this study, we establish for the first time that COX inhibitors differentially modulate endogenous p73 isoforms in neuroblastoma and that COX inhibitor-induced downregulation of the DNp73 AS splice variants is mediated through the inhibition of E2F-1 activity.
Results

COX inhibitors suppress cell growth in neuroblastoma
We have previously demonstrated that selective and non-selective COX inhibitors induce cell death in neuroblastoma, in part due to p53-dependent apoptosis (Lau et al., 2007) . The selective COX-2 inhibitor celecoxib also suppressed the proliferation of p53-mutant neuroblastoma cells (SK-N-BE2, SK-N-FI and SK-N-AS) in vitro ( Figure 2a ) and inhibited the growth of SK-N-BE2 xenografts (data not shown). Nonselective COX inhibitors (diclofenac and indomethacin) and the celecoxib analog OSU03012 also induced the growth inhibition of p53-mutant and wt neuroblastoma cell lines (data not shown). Importantly, celecoxib and OSU03012 inhibited the growth of patient-derived primary neuroblastoma tumor-initiating cells (Figure 2b ) that have recently been shown to have cancer stem cell properties . Furthermore, chemotherapy (doxorubicin) combined with different doses of celecoxib (5 to 50 mm) resulted in synergistic (combination index (CI) o 1) or additive (CI ¼ 1) effects in p53 mutant SK-N-BE2 cells (Figure 2c ). Although we have previously shown that COX inhibitors can activate p53/HDM2-dependent apoptotic pathway (Lau et al., 2007) , these results support that COX inhibitors can also inhibit neuroblastoma cell growth through p53-independent pathways. The prognosis of neuroblastoma and its sensitivity to therapy are influenced by various genetic characteristics including MYCN gene copy number, p53 mutation and 1p status and the presence of chromosomal gains and losses (Maris et al., 2007; Xue et al., 2007) . Importantly, the IC 50 of celecoxib for neuroblastoma cell lines with different genetic profiles (Supplementary Table 1) were similar (B50 mM) (Figure 2a ), suggesting that celecoxib can suppress cell growth independent of p53, MYCN and 1p status. Gene and protein structure of p73 isoforms. (a) The structure of p73 isoforms. p73 encodes multiple isoforms due to alternative promoter (AP) utilization and alternative splicing (AS) at both NH 2 -and COOH-termini. Transactivation (TA) isoforms are transcribed from the P1 promoter, located in the 5 0 untranslated region of exon 1. DNp73 AP isoforms are generated from an alternative cryptic promoter (AP or P2) located within intron 3. AS of the P1 transcripts at the N-terminus gives rise to two of the DNp73
AS isoforms-Dexon2 and Dexon2/3 p73 (also referred to as DTAp73 in some reports). Arrows represent transcription start sites. Non-coding sequences are depicted in black. (b) The exon structure of DNp73 AP and DNp73 AS is compared with that of TAp73 (only the first five exons are depicted). Both DNp73 AP and DNp73 AS lack the TA domain (exons 2 and 3) and act as dominant-negative inhibitors of p53 and TAp73. (c) Splicing at the COOH-terminus generates multiple isoforms (a-y); shown are the a-and b-isoforms. TAp73a is the full-length (FL) protein that contains the TA domain, DNA-binding domain (DBD), oligomerization domains (OD) and the sterile-a motif (SAM). TAp73b lacks the SAM domain due to splicing of exon 13.
TAp73b induction by COX inhibitors
As p53-mutant cells were sensitive to COX inhibitors, we next asked whether like many chemotherapies, celecoxib modulation of the p53 homolog p73 could mediate apoptosis. Celecoxib-induced apoptosis, as measured by poly-ADP-ribose polymerase (PARP) cleavage, was associated with dose-dependent increases in the levels of the proapoptotic TAp73b isoform in wt (IMR-5) and p53-mutant (SK-N-BE2) neuroblastoma cells, both of which are MYCN amplified and 1p deleted (Figure 3a) . Celecoxib in combination with doxorubicin resulted in synergistic induction of TAp73b in p53 mutant SK-N-BE2 (Supplementary Figure 1a) . TAp73b induction was also observed in neuroblastoma cell lines without MYCN amplification or 1p deletion (Supplementary Figure 1b) , as well as in other tumor types including sarcomas and squamous cell carcinomas (Supplementary Figure 1c) . TAp73b detection was confirmed using both b-specific (GC-15) and TA-specific (BL-906) p73 antibodies (Supplementary Figure 1d) . Non-selective COX inhibitors (diclofenac and indomethacin) also induced TAp73b (Supplementary Figure  1e) . In contrast, TAp73a levels decreased after celecoxib treatment (Supplementary Figure 1f) . To determine whether increased TAp73b expression following celecoxib treatment leads to the induction of downstream target genes, we examined changes in the levels of puma and noxa, as well as p57 kip2 , a target previously shown to be selectively induced by TAp73b and required for TAp73b-induced apoptosis (Balint et al., 2002; Gonzalez et al., 2005) . We found that celecoxib increased puma, noxa and p57 kip2 levels in a dose-dependent manner (Figure 3b ). Similar p57 kip2 induction was also observed in primary neuroblastoma cells (Figure 3c ). We next performed reverse transcriptase PCR (RT-PCR) to determine whether increased TAp73b protein was associated with increased TAp73b transcription. Using isoform-specific primers, we found that p73b and TAp73 (Figure 3d ), as well as p73a mRNA levels (data not shown) decreased following celecoxib treatment. We, therefore, measured TAp73b half-life. In contrast with p53 (Lau et al., 2007) , TAp73b half-life was only slightly increased by celecoxib as determined by pulsechase assay (data not shown). Next, to ask whether the induction of TAp73b protein leads to the induction of proapoptotic genes, we utilized cells engineered to overexpress a small p73 dominant-negative (p73DD), which inhibits TAp73 and p63, but not p53, activity ( Irwin et al., 2000 Irwin et al., , 2003 . Importantly, human embryonic kidney (HEK) cells (data not shown) and SK-N-BE2 cells (Lau et al., 2008) used in these experiments do not express p63. After celecoxib treatment, lower levels of noxa and the TAp73b-specific target p57 kip2 were observed in HEK cells with stable p73D expression ( Figure 3e ). Furthermore, transient overexpression of p73DD in p53-mutant SK-N-BE2 neuroblastoma cells also resulted in diminished cleaved-PARP in response to celecoxib (Supplementary Figure 1g) . Taken together, these results support that celecoxib-mediated cell death is, at least in part, dependent on TAp73b.
COX inhibitors downregulate the antiapoptotic DNp73
AS
Neuroblastoma and other cancer cells types express high levels of DNp73 proteins that would be predicted to inhibit the proapoptotic TAp73 isoforms and p53 (Buhlmann and Putzer, 2008) . Thus, we specifically examined the effect of COX inhibitors on the levels of DNp73 isoforms. In contrast with the induction of TAp73b, the expression levels of DNp73a splice variants (DNp73 AS ), generated by AS of exon 2 (Dexon2 p73) or exons 2 and 3 (Dexon2/3 p73), decreased after treatment with celecoxib in both neuroblastoma cell lines and primary cells (Figure 4a ). DNp73
AS downregulation was also observed with diclofenac and indomethacin (Supplementary Figure 2a) , and in neuroblastoma xenografts ( Supplementary Figure 2b) , as well as in non-neuroblastoma cells (data not shown). Celecoxib, in combination with doxorubicin, also resulted in synergistic downregulation of DNp73 Figure 2c) . The identity of these bands was confirmed using a p73a-specific antibody (Ab2301) against the sterile-alpha motif (SAM) domain of p73a and by comigration with transfected DNp73
AS (Supplementary
AS (Supplementary Figures 2d and e). To determine whether COX inhibitors affect DNp73
AS transcription, we performed semiquantitative RT-PCR. Treatment with celecoxib led to significant downregulation of both Dexon2 p73 and Dexon2/3 p73 mRNA in IMR-5 and SK-N-BE2 cells (Figure 4b ). Similar results were seen with diclofenac ( Supplementary Figure 2f) . DNp73
AS mRNA expression was also decreased by celecoxib in neuroblastoma xenografts (Supplementary Figure 2b) , as well as in additional neuroblastoma cell lines, primary neuroblastoma cells and in non-neuroblastoma cells (Supplementary Figure 2g) . Although DNp73 isoforms can also be generated by transcription from a cryptic AP in intron 3, celecoxib had no significant effect on DNp73 AP mRNA (Figure 4c ). DNp73 isoforms lack the TA domain ( Figure 1 ) and act as dominant-negative inhibitors of TAp73 and wtp53. Hence the downregulation of DNp73
AS by COX inhibitors would be expected to promote the activation of TAp73 and p53 target genes and induce apoptosis. Transfection of plasmids encoding Dexon2 and Dexon2/3 p73a rescued both IMR-5 and SK-N-BE2 cells from celecoxib-induced apoptosis, as shown by diminished PARP cleavage and decreased expression of the downstream targets puma, noxa and p21 cip1/waf1 (Figure 4d ). Several previous reports have shown that DNp73 AS inhibition of p53 activity is due to the competition for p53/p73-binding sites at target genes (Fillippovich et al., 2001; Stiewe et al., 2002) . The DNp73 protein generated from the P2 promoter (DNp73 AP ) has also been shown to form a transactivation-deficient complex with wt-p53 in certain cellular contexts (Pozniak et al., 2000; Zaika et al., 2002) ; however, DNp73
AS binding to wt-p53 has not been reported. We performed coimmunoprecipitations to show in vitro association between DNp73 AS and p53 (Supplementary Figure 3a) ; and for the first time, an endogenous wt-p53 and Dexon2/3 heterocomplex (Supplementary Figure 3b) . Reduction of DNp73 AS /p53 and DNp73 AS /TAp73 heterocomplexes by celecoxib would be expected to result in increased levels of free p53 and TAp73, respectively. We have earlier shown that in cells with wt-p53, the activity of p53 is required for apoptosis in response to COX inhibitors (Lau et al., 2007) . To examine whether reduction in DNp73 AS /TAp73 heterocomplexes would lead to enhanced TAp73b activity, we performed sequential immunoprecipitations. After immunodepletion of these DNp73
AS a-containing complexes, higher levels of free TAp73b ( Supplementary  Figure 3c) , as well as enhanced TAp73b binding to the p57 kip2 promoter (Supplementary Figure 3d) , were detected in celecoxib-treated cells. Taken together, these results support that celecoxib-induced apoptosis is, at least in part, due to the downregulation of DNp73
AS .
Inhibition of E2F-1 TA of p73 by celecoxib To elucidate the mechanisms by which celecoxib downregulates DNp73
AS , we investigated the potential role of the transcription factor E2F-1. We and others have shown that E2F-1 binds to several E2F consensus sites in the p73 P1 promoter leading to the enhanced transcription of TAp73 and the DNp73 AS variants (Irwin et al., 2000; Stiewe and Putzer, 2000; Putzer et al., 2003) . Thus, we hypothesized that celecoxib-mediated effects on DNp73
AS mRNA were due to the inhibition of E2F-1 transactivation of p73. After celecoxib treatment, E2F-1 levels decreased in a dose-dependent manner in both IMR-5 and SK-N-BE2 cells (Figure 5a ). We next studied the effects of celecoxib on previously described p73 promoter luciferase reporters (Irwin et al., 2000) ( Figure 5b ). p73 promoter (FL) activity was reduced by 70% after celecoxib treatment (Figure 5b) , suggesting an inhibitory effect of celecoxib on the p73 promoter. To determine whether this drug-induced inhibition of activity was due to E2F-1, a plasmid encoding E2F-1 was cotransfected with luciferase reporter plasmids. Exogenous wt E2F-1, but not a DNA-binding-defective E2F-1 mutant (E2F-1(132E) ), induced p73 promoter activity (Figure 5b ), which was inhibited by celecoxib in a dose-dependent manner (Figure 5c ). In comparison with the FL reporter, the À218 deletion P1 reporter, which contains two of the three E2F-binding sites was only partially activated by exogenous E2F-1, and like FL, its activity was reduced by approximately 70% after celecoxib treatment ( Figure 5b ). As expected, the À117 deletion reporter, which lacks E2F-binding sites, was not activated by E2F-1 or affected by drug treatment. Moreover, a luciferase reporter plasmid encoding the P2 promoter was not activated by E2F-1 (data not shown), consistent with the observation that celecoxib has no significant effects on DNp73 AP transcription (Figure 4c ). To determine whether celecoxib inhibits E2F-1 recruitment to the p73 P1 promoter, we performed chromatin immunoprecipitation (ChIP ) and showed that celecoxib inhibited E2F-1 binding to the P1 promoter (Figure 5d ). Taken together, these data suggest that in response to celecoxib treatment, downregulation of E2F-1 leads to diminished activation of the p73 P1 promoter resulting in decreased transcription of DNp73 AS .
Role of COX-2 in celecoxib-mediated effects
Both selective COX-2 and non-selective COX1/2 inhibitors have been shown to induce apoptosis through COX-2 dependent and independent pathways (Kashfi and Rigas, 2005; Grosch et al., 2006) . Thus, we next asked whether the apoptosis and changes in p73 observed in neuroblastoma cells were dependent on COX-2 activity after celecoxib treatment. First, we examined neuroblastoma sensitivity to OSU03012, a celecoxib derivative that lacks the ability to inhibit COX-2 enzymatic activity (Zhu et al., 2004) . OSU03012 treatment induced growth inhibition and PARP cleavage (Figures 2b and 6a) . Interestingly, although OSU03012 does not inhibit COX-2, like celecoxib (lanes 3 and 4) . DNA extracts from both input (lanes 1 and 2) and immunoprecipitates (lanes 3 to 6) were subjected to PCR with primers amplifying a region encompassing the E2F-1 binding sites on the p73 or GADPH promoter. treatment, OSU03012 is still associated with decreased E2F-1 and DNp73 AS levels, and increased p53 ( Figure 6a ). Next, we determined that COX-2 levels do not change significantly upon the addition of selective or non-selective COX inhibitors (Supplementary Figure 4) . Furthermore, in contrast with other cell types, we detected low levels of prostaglandin E2, a downstream target synthesized through the COX pathway, and these levels did not change after treatment with COX inhibitors (data not shown). Finally, Shortinterfering RNA (siRNA) knockdown of COX-2 did not significantly affect celecoxib-induced PARP cleavage (Figure 6b ). In addition, COX-2 siRNA did not rescue the downregulation of DNp73
AS and E2F-1 observed in response to celecoxib treatment (Figure 6b) . Thus, although we cannot formally rule out the possibility that the observed effects are in part COX-2 dependent, the large body of literature (Kashfi and Rigas, 2005; Grosch et al., 2006) and our current findings suggest that these effects are, at least in part, COX-2 independent. Discussion p73 is an important determinant of cellular response to anticancer agents (Irwin, 2004) . Although p73 is rarely mutated in cancer, p73 encodes both proapoptotic and antiapoptotic isoforms. There is increasing evidence that the TAp73:DNp73 ratio, as well as the balance between different p53 (wt or mutant), p73 and p63 isoforms, determine the apoptotic fate of cancer cells. The specific TAp73:DNp73 ratio has also been linked to clinical prognosis and chemosensitivity (Casciano et al., 2002; Concin et al., 2005; Muller et al., 2005; Dominguez et al., 2006) . p53 is frequently inactivated in tumors; therefore, manipulating the ratio of the various p73 isoforms to promote apoptosis is an attractive strategy, not only to overcome chemoresistance in cell systems haboring p53 mutations, but also to enhance chemosensitivity in tumors with wt-p53. COX inhibitors are anti-inflammatory agents that exhibit anticancer properties (Thun et al., 2002) , and have been shown by us to regulate p53, and now p73, in neuroblastoma. Recently, we reported that COX inhibitors induce apoptosis by regulating the p53/HDM2 pathway leading to the increased p53 stability and nuclear accumulation (Lau et al., 2007) . In this study, we show for the first time that celecoxib downregulates the antiapoptotic DNp73 AS (DTAp73) isoforms, and at the same time, induce the proapoptotic TAp73b isoform. Although p63 isoforms also play important roles in tumorigenesis (Flores et al., 2005) , the lack of p63 expression in neuroblastoma cell lines and primary tumor suggests that treatment with COX inhibitors affects the balance between the two major p53 family proteins in neuroblastoma, p53 and p73.
Our data suggest that growth inhibition and changes in p73 expression occur at physiologic doses of celecoxib. First, modulation of p73 isoforms was detected at concentrations as low as 10 mM in vitro. Second, in combination with chemotherapy, we detected additive and synergistic effects with celecoxib doses of 5-10 mM. Although pharmacokinetic data in children suggests peak levels in the 5 mM range (Stempak et al., 2002) , the target tissue drug concentration is not known, and it is difficult to measure the final effective dosage in serum-containing media because celecoxib is >95% protein bound. However, particularly in murine xenografts, we and others have observed growth inhibition with celecoxib at dosages that result in measured peak levels in the 5 mM range (Ponthan et al., 2007) , and at (a) cleaved-PARP, E2F-1, p73a (Ab2301), p53 (DO-1) and vinculin immunoblots of IMR-5 cells treated with OSU03012 at the indicated doses for 48 h. (b) IMR-5 cells were transfected with the indicated COX-2 siRNA oligonucleotides. siCONTROL (Dharmacon) was used as siRNA control. After 24 h, cells were treated with celecoxib (50 mM) for 48 h. Lysates were subjected to immunoblotting with COX-2, cleaved-PARP, p73a (Ab2301), E2F-1 and vinculin antibodies. Asterisk represents a non-specific band as described in Supplementary Figure 2d . COX-2 protein knockdown was measured to be between 40 and 80% of control adjusted for vinculin-loading control (data not shown). Results are representative of three independent experiments. COX, cyclooxygenase; siRNA, short-interfering RNA.
these doses, we also detected the downregulation of DNp73, similar to the effects observed in vitro. Taken together with our synergy data using low-dose celecoxib, the efficacy in xenografts provides evidence for in vivo p73 modulation associated with tumor growth inhibition at doses that are achievable in pediatric patients. Furthermore, the celecoxib analog OSU03012 has shown efficacy in other cell lines (Johnson et al., 2005) , and we found that treatment at nanomolar doses resulted in growth inhibition and modulation of p73 in neuroblastoma.
Overexpression of DNp73 isoforms confers poor prognosis in many cancers including neuroblastoma (Casciano et al., 2002; Concin et al., 2005; Muller et al., 2005; Dominguez et al., 2006) . DN isoforms can be generated from the alternative P2 promoter at intron 3 (DNp73 AP ) or, like the TA isoforms, are derived from the P1 promoter followed by splicing at the NH 2 -terminus (DNp73 AS ). Distinguishing the levels and regulatory mechanisms for the different isoforms at the endogenous level has been hampered by the lack of isoform-specific antibodies . In this study, we show that COX inhibitors (celecoxib and diclofenac) downregulate endogenous protein and mRNA levels of DNp73 AS isoforms, Dexon2 and Dexon2/3 p73, in multiple neuroblastoma cell lines in vitro and in vivo and in primary tumor-initiating cells, as well as several rhabdomyosarcoma and squamous cell carcinoma cell lines. The p73 P1 promoter harbors several E2F consensus-binding sites (Irwin et al., 2000; Stiewe and Putzer, 2000) . We show that COX inhibitor treatment decreases DNp73 AS transcription by the downregulation of E2F-1. This is supported by celecoxib-mediated downregulation of DNp73 AS transcripts, p73 P1 reporter activities and decreased E2F-1 binding at the p73 P1 promoter, as well as a recent report showing that celecoxib induces apoptosis and cell cycle arrest through the inhibition of nuclear E2F-1 expression and activity in head-and-neck squamous cell carcinoma (Bock et al., 2007) . In contrast with the downregulation of the P1-generated DNp73 AS ,
DNp73
AP isoforms transcribed from the P2 promoter were unaffected, suggesting that the inhibitory effect is P1 promoter specific. Additional studies are needed to elucidate the mechanism(s) by which celecoxib affects E2F-1 expression; however, these effects are likely COX-2 independent because COX-2 siRNA did not rescue the downregulation of E2F-1/p73, and treatment with the celecoxib analog OSU03012 that lacks COX inhibitory activity, led to similar E2F-1/p73 effects (Zhu et al., 2004) . Interestingly, in numerous studies, cancer cells that do not express endogenous COX-2, cox2À/À fibroblasts and cells treated with COX-2 antisense, are still sensitive to selective and non-selective COX inhibitors. Our earlier data (Lau et al., 2007) together with the work presented above support a role for the E2F-1, p73 and p53 in COX-2-independent cell death pathways.
E2F-1 is known to have dual roles in cell cycle progression and apoptosis (Putzer, 2007) . E2F-1 transactivation of proapoptotic targets has been proposed as a therapeutic strategy. Our data raise an important caveat as to the efficacy of therapies aimed at the induction of TAp73 through E2F-1 activation in tumors expressing high levels of DNp73
AS isoforms. In a recent study of breast and colon cancer, overexpression of DNp73
AS isoforms was associated with high levels of E2F-1 as well as poor prognosis (Dominguez et al., 2006) . Furthermore, Putzer et al. (2003) reported high levels of P1-generated DNp73
AS isoforms in hepatocellular carcinoma and showed the upregulation by E2F-1 and associated chemoresistance. In our study, high levels of DNp73 AS in neuroblastoma are downregulated by COX inhibitors, and this modulation is, at least in part, due to diminished E2F-1 activity. Although reduction of TAp73 mRNA by COX inhibitors might be expected to inhibit apoptosis, the concurrent downregulation of DNp73
AS , together with the induction of TAp73b protein, leads to a shift in the balance between TA and DNp73 favoring apoptosis. The induction of p53 and TAp73 targets following COX inhibitor treatment is, at least in part, due to the downregulation of DNp73
AS as overexpression of DNp73 AS or specific p73 dominant-negative protein p73DD results in diminished expression of these proapoptotic target genes. Furthermore, we show that diminished DNp73
AS results in more free TAp73b and transcription of the p73b-specific target p57 kip2 . TAp73b is reported to be a more potent apoptosis inducer than TAp73a (Gonzalez et al., 2005) . Thus, the increased TAp73b expression mediated by COX inhibitors leads to apoptosis despite decreased levels of TAp73a. Our results with p73DD mutant proteins that inhibit TAp73b support this conclusion and have been used by our group and others to show a role for TAp73 in drug-induced cell death (Irwin et al., 2003; Amin et al., 2007) . Unfortunately, specific knockdown of endogenous TAp73b has not been reported in the literature and is technically hampered by the fact that exons 12 and 14 are present in both p73a and p73b, and the only b-specific base pairs are those that span the 'junction' of exon 12/14 due to the splicing of exon 13. The mechanism of p73 isoform regulation at mRNA level is likely mediated by COX inhibitor downregulation of E2F-1; however, the mechanism for selective induction of TAp73b protein expression has yet to be determined. The half-life of TAp73b is slightly increased by celecoxib treatment; thus, one possibility is that the unique C-terminal b-residues not present in p73a may be involved in p73 turnover processes. It remains plausible that post-transcriptional effects of celecoxib may further affect selective induction of TAp73b, and further studies are required to identify the mechanism for this previously undescribed unique b-stabilization. Earlier, we have shown that apoptosis in response to COX inhibitors is in part dependent on p53. Taken together with our current data, it is likely that the effects on the balance between the pro-and antiapoptotic isoforms of p53 and p73 in neuroblastoma are a critical determinant of drug sensitivity.
In conclusion, we provide the first evidence that COX inhibitors differentially modulate endogenous p73 isoforms in neuroblastoma, as well as in other tumor types, and that the downregulation of DNp73
AS is mediated through E2F-1 inhibition. As DNp73 overexpression and/or E2F-1 deregulation are reported in many tumors, combining COX inhibitors with chemotherapeutic agents, especially those that can also induce TAp73a, is therefore potentially an attractive therapeutic strategy, and further supported by the in vitro and in vivo synergism observed in neuroblastoma when COX inhibitors are combined with chemotherapy (Lau et al., 2007; Ponthan et al., 2007) . Table 1) were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, non-essential amino acids and sodium pyruvate. Primary neuroblastoma cells (NB12 and NB61), derived from bone marrow metastases of neuroblastoma patients, were grown as spheres in neural crest stem cells conditions as described earlier . Additional cell line details are described in supplementary data. Celecoxib (Toronto Research Chemical, Toronto, ON, Canada), diclofenac, indomethacin and OSU03122 (Cayman Chemicals, Ann Arbor, MI, USA) were dissolved in dimethyl sulfoxide (final dimethyl sulfoxide concentration during drug treatment was o0.05%).
Materials and methods
Cell culture and drugs Neuroblastoma cells (Supplementary
Cell proliferation assays
Cell proliferation was measured with the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Roche Applied Science, Laval, QC, Canada). For combination treatment, doses equivalent to 1/10, 1/5, 1/2, and 1/1 of the IC 50 of celecoxib, and 1/2 and 1/1 of the IC 50 of doxorubicin were used. Drug combination effect was measured using the CI and the CalcuSyn software (Biosoft, Cambridge, UK) as described earlier (Lau et al., 2007) . CI ¼ 1 indicates an additive effect, whereas CI o1 and CI >1 indicate synergism and antagonism, respectively. Growth assays of primary cells are described in supplementary data.
Xenograft studies NOD/SCID mice with established SK-N-BE2 xenografts were treated with celecoxib (75 mg/kg/day). Animals were killed on days 0, 3 and 9 of treatment, and tumors were analysed for p73 protein and RNA expression. Details of experiment are available in supplementary data.
Immunoblotting and immunoprecipitation
Cell lysis and immunoblotting were performed as described earlier (Lau et al., 2007 (Lau et al., , 2008 . Details of lysis, immunoprecipitations, sequential immunodepletion experiments and specific antibody information are available in supplementary information.
Plasmids, transfection and luciferase reporter assays pcDNA3-Dexon2p73 and Dexon2/3p73 were kindly provided by Dr T Stiewe (Stiewe et al., 2002) . pGL3-p73 P1 promoter luciferase plasmids, pRc-CMV-HA-E2F-1, pRc-CMV-HA-E2F-1(132E) and T7-p73DD were described earlier (Irwin et al., 2000) . Cells were transfected using Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada) with a ratio of 1 mL lipofectamine to 1 mg DNA. For luciferase reporter assays, cells were transfected with a reporter plasmid (pGL3) containing the indicated p73 reporter (FL, À218 or À117) (200 ng) and Renilla luciferase (1 ng), as well as wt or mutant E2F-1 (100 ng; when indicated). The total amount of DNA in each sample was normalized to 300 ng with pcDNA3. Luciferase activity was quantified and normalized to Renilla activity for transfection efficiency using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA).
RT-PCR
Total RNA was extracted using TRIzol (Invitrogen). cDNA was generated using the Omniscript RT Kit (Qiagen, Mississauga, ON, Canada) and amplified by semiquantitative RT-PCR using the Taq DNA polymerase Kit (Qiagen). See supplementary information for primer sequences and PCR conditions.
ChIP
Chromatin immunoprecipitation assays were performed to detect E2F-1-p73 P1 promoter and TAp73b-p57 kip2 promoter binding. Cells were fixed with 1% formaldehyde and quenched with 125 mM glycine. Cell were lysed in ChIP lysis buffer containing 0.1% NP-40, 1% Triton X-100, 1 mM EDTA, 60 mM KCl, 100 mM NaCl, 20 mM Tris-HCl (pH 7.4) and protease inhibitors, followed by sonication. For E2F-1-p73 promoter binding, whole cell extract (WCE) were precleared with protein A Sepharose slurry and immunoprecipitated with E2F-1 (C-20) or HA (Y11) antibody and protein A Sepharose beads (preblocked with salmon sperm DNA). For TAp73b-p57 kip2 promoter binding, WCE were sequentially immunodepleted five times with the p73a-specific (Ab2301) antibody and protein A Sepharose beads, followed by immunoprecipitation with TAp73-specific (BL-906) antibody and salmon sperm DNA preblocked protein A Sepharose beads. The protein-DNA complex was eluted with elution buffer (1% SDS and 10 mM NaHCO 3 ). Cross-linking was reversed in both eluate and input by incubation with Proteinase K (10 mg/ml) at 65 1C overnight. DNA was extracted with phenol-chloroform and amplified by PCR using the Taq DNA polymerase Kit (Qiagen). ChIP PCR conditions and primers are detailed in supplementary information. siRNA Short-interfering RNA was performed as described earlier (Lau et al., 2007) using siRNA target sequences COX-2-1: 5 0 AAACATCCAGATCACATTTGA3 0 ; COX-2-2: 5 0 TGAAA GGACTTATGGGTAA3 0 ; COX-2-3: 5 0 CAAATGAGATTG TGGAAAA3 0 (Dharmacon, Lafayatte, CO, USA).
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